IDEXX Laboratories, Inc. $IDXX Shares Bought by Choreo LLC

Choreo LLC raised its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 74.0% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 2,687 shares of the company’s stock after buying an additional 1,143 shares during the quarter. Choreo LLC’s holdings in IDEXX Laboratories were worth $1,441,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Mutual of America Capital Management LLC lifted its holdings in shares of IDEXX Laboratories by 79.6% during the first quarter. Mutual of America Capital Management LLC now owns 19,430 shares of the company’s stock valued at $8,160,000 after purchasing an additional 8,609 shares during the last quarter. Arkadios Wealth Advisors acquired a new stake in IDEXX Laboratories during the 2nd quarter worth about $405,000. Plato Investment Management Ltd lifted its stake in IDEXX Laboratories by 37.1% during the first quarter. Plato Investment Management Ltd now owns 3,087 shares of the company’s stock valued at $1,310,000 after buying an additional 835 shares in the last quarter. Genesis Wealth Advisors LLC acquired a new position in shares of IDEXX Laboratories in the second quarter worth about $215,000. Finally, ORG Wealth Partners LLC purchased a new position in shares of IDEXX Laboratories in the second quarter worth approximately $273,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Down 0.4%

Shares of IDEXX Laboratories stock opened at $753.05 on Friday. The firm has a market cap of $60.13 billion, a price-to-earnings ratio of 62.70, a P/E/G ratio of 4.06 and a beta of 1.62. The stock has a 50-day simple moving average of $666.95 and a 200-day simple moving average of $605.72. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $769.98. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Monday, November 3rd. The company reported $3.22 earnings per share for the quarter, beating the consensus estimate of $3.14 by $0.08. The firm had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The company’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same quarter last year, the firm earned $2.80 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. On average, equities research analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. JPMorgan Chase & Co. upped their price target on shares of IDEXX Laboratories from $675.00 to $775.00 and gave the company an “overweight” rating in a research report on Tuesday, November 4th. Piper Sandler restated a “neutral” rating and issued a $700.00 target price (up previously from $510.00) on shares of IDEXX Laboratories in a report on Monday, August 11th. BTIG Research raised their target price on IDEXX Laboratories from $785.00 to $830.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Jefferies Financial Group reissued a “buy” rating and set a $830.00 price target on shares of IDEXX Laboratories in a research report on Tuesday, November 4th. Finally, Leerink Partners set a $785.00 price objective on IDEXX Laboratories in a research note on Monday, November 3rd. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $730.50.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 9,425 shares of the stock in a transaction on Friday, November 7th. The shares were sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the transaction, the executive vice president directly owned 21,149 shares of the company’s stock, valued at $14,874,937.66. This represents a 30.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 0.98% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.